Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
出版年份 2016 全文链接
标题
Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both
作者
关键词
-
出版物
LEUKEMIA
Volume 30, Issue 5, Pages 1018-1024
出版商
Springer Nature
发表日期
2016-02-08
DOI
10.1038/leu.2016.12
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells
- (2015) M. Lu et al. BLOOD
- Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
- (2015) J. D. Milosevic Feenstra et al. BLOOD
- Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients
- (2015) X. Cabagnols et al. BLOOD
- The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
- (2015) M. Deininger et al. BLOOD
- Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells
- (2015) Robert S. Welner et al. CANCER CELL
- CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
- (2015) Sara C. Meyer et al. CANCER CELL
- The Hen or the Egg: Inflammatory Aspects of Murine MPN Models
- (2015) Jonas S. Jutzi et al. MEDIATORS OF INFLAMMATION
- Recombinant interferon-α in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response
- (2015) Marco Pizzi et al. MODERN PATHOLOGY
- Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6
- (2015) Qian Zhang et al. NATURE
- Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera
- (2015) Alessandro M. Vannucchi et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK-STAT Pathway Activation in Malignant and Nonmalignant Cells Contributes to MPN Pathogenesis and Therapeutic Response
- (2015) M. Kleppe et al. Cancer Discovery
- Rationale for combination therapy in myelofibrosis
- (2014) John Mascarenhas BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
- (2014) E. Rumi et al. BLOOD
- Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
- (2014) Neha Bhagwat et al. BLOOD
- Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms
- (2014) Hans C Hasselbalch Expert Review of Hematology
- Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon- in a murine model of polycythemia vera
- (2013) A. Mullally et al. BLOOD
- JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN
- (2013) S. Hasan et al. BLOOD
- Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia
- (2013) G. Rotunno et al. BLOOD
- The role of cytokines in the initiation and progression of myelofibrosis
- (2013) Hans C. Hasselbalch CYTOKINE & GROWTH FACTOR REVIEWS
- Transcription factor nuclear factor erythroid-2 mediates expression of the cytokine interleukin 8, a known predictor of inferior outcome in patients with myeloproliferative neoplasms
- (2013) J. Wehrle et al. HAEMATOLOGICA
- MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
- (2013) Jonas S. Jutzi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis
- (2013) T Barbui et al. LEUKEMIA
- A role of NF-E2 in chronic inflammation and clonal evolution in essential thrombocythemia, polycythemia vera and myelofibrosis?
- (2013) Hans C. Hasselbalch LEUKEMIA RESEARCH
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bone Marrow Injury Induced via Oxidative Stress in Mice by Inhalation Exposure to Formaldehyde
- (2013) Yuchao Zhang et al. PLoS One
- Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
- (2013) Richard T Silver et al. Expert Review of Hematology
- Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer?
- (2012) H. C. Hasselbalch BLOOD
- Genetic and epigenetic alterations of myeloproliferative disorders
- (2012) Jelena D. Milosevic et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2
- (2012) Kai B. Kaufmann et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Chronic inflammation as a promotor of mutagenesis in essential thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation model for cancer development?
- (2012) Hans Carl Hasselbalch LEUKEMIA RESEARCH
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- TNF facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms
- (2011) A. G. Fleischman et al. BLOOD
- Recombinant interferon- may retard progression of early primary myelofibrosis: a preliminary report
- (2011) R. T. Silver et al. BLOOD
- The renaissance of interferon therapy for the treatment of myeloid malignancies
- (2011) J.-J. Kiladjian et al. BLOOD
- IL-6 Controls Leukemic Multipotent Progenitor Cell Fate and Contributes to Chronic Myelogenous Leukemia Development
- (2011) Damien Reynaud et al. CANCER CELL
- Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms
- (2011) Gregor Hoermann et al. FASEB JOURNAL
- European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis
- (2011) T. Buhr et al. HAEMATOLOGICA
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
- (2011) Ayalew Tefferi et al. JOURNAL OF CLINICAL ONCOLOGY
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2
- (2010) W. Wang et al. BLOOD
- Inflammatory Bowel Disease as a Risk Factor for Colorectal Cancer
- (2010) Milan Lukas DIGESTIVE DISEASES
- Of mice and men: Human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells
- (2010) Roland Roelz et al. EXPERIMENTAL HEMATOLOGY
- Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
- (2010) Min Lu et al. EXPERIMENTAL HEMATOLOGY
- Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3
- (2010) T. Barbui et al. HAEMATOLOGICA
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- (2009) N. Kroger et al. BLOOD
- Bone Morphogenetic Proteins Are Overexpressed in the Bone Marrow of Primary Myelofibrosis and Are Apparently Induced by Fibrogenic Cytokines
- (2008) Oliver Bock et al. AMERICAN JOURNAL OF PATHOLOGY
- The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
- (2008) C. S. Tam et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started